212 related articles for article (PubMed ID: 36029101)
1. Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy.
Schwab ME; Shao S; Zhang L; Lianoglou B; Belter L; Jarecki J; Schroth M; Sumner CJ; MacKenzie T
Prenat Diagn; 2022 Oct; 42(11):1409-1419. PubMed ID: 36029101
[TBL] [Abstract][Full Text] [Related]
2. Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients.
Schwab ME; Brown JEH; Lianoglou B; Jin C; Conroy PC; Gallagher RC; Harmatz P; MacKenzie TC
Orphanet J Rare Dis; 2022 Jan; 17(1):25. PubMed ID: 35093147
[TBL] [Abstract][Full Text] [Related]
3. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
4. Evolving approaches to prenatal genetic counseling for Spinal Muscular Atrophy in the new treatment era.
Zettler B; Estrella E; Liaquat K; Lichten L
J Genet Couns; 2022 Jun; 31(3):803-814. PubMed ID: 35037741
[TBL] [Abstract][Full Text] [Related]
5. Prenatal diagnosis of spinal muscular atrophy by genetic analysis of circulating fetal cells.
Béroud C; Karliova M; Bonnefont JP; Benachi A; Munnich A; Dumez Y; Lacour B; Paterlini-Bréchot P
Lancet; 2003 Mar; 361(9362):1013-4. PubMed ID: 12660061
[TBL] [Abstract][Full Text] [Related]
6. SMN1 dosage analysis in spinal muscular atrophy from India.
Kesari A; Rennert H; Leonard DG; Mittal B
BMC Med Genet; 2005 May; 6():22. PubMed ID: 15910686
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
[TBL] [Abstract][Full Text] [Related]
8. Circulating trophoblastic cells provide genetic diagnosis in 63 fetuses at risk for cystic fibrosis or spinal muscular atrophy.
Mouawia H; Saker A; Jais JP; Benachi A; Bussières L; Lacour B; Bonnefont JP; Frydman R; Simpson JL; Paterlini-Brechot P
Reprod Biomed Online; 2012 Nov; 25(5):508-20. PubMed ID: 23000084
[TBL] [Abstract][Full Text] [Related]
9. Prenatal Carrier Screening for Spinal Muscular Atrophy.
Wood SL; Brewer F; Ellison R; Biggio JR; Edwards RK
Am J Perinatol; 2016 Oct; 33(12):1211-7. PubMed ID: 27611803
[TBL] [Abstract][Full Text] [Related]
10. Prenatal prediction of spinal muscular atrophy in Chinese.
Lin SP; Chang JG; Jong YJ; Yang TY; Tsai CH; Wang NM; Li H; Hsieh-Li HM; Hu CJ
Prenat Diagn; 1999 Jul; 19(7):657-61. PubMed ID: 10419615
[TBL] [Abstract][Full Text] [Related]
11. Prenatal diagnosis of spinal muscular atrophy in Macedonian families.
Kocheva SA; Plaseska-Karanfilska D; Trivodalieva S; Kuturec M; Vlaski-Jekic S; Efremov GD
Genet Test; 2008 Sep; 12(3):391-3. PubMed ID: 18752447
[TBL] [Abstract][Full Text] [Related]
12. Transmission ratio distortion in the spinal muscular atrophy locus: data from 314 prenatal tests.
Botta A; Tacconelli A; Bagni I; Giardina E; Bonifazi E; Pietropolli A; Clementi M; Novelli G
Neurology; 2005 Nov; 65(10):1631-5. PubMed ID: 16301493
[TBL] [Abstract][Full Text] [Related]
13. Prenatal prediction in families with autosomal recessive proximal spinal muscular atrophy (5q11.2-q13.3): molecular genetics and clinical experience in 109 cases.
Wirth B; Rudnik-Schöneborn S; Hahnen E; Röhrig D; Zerres K
Prenat Diagn; 1995 May; 15(5):407-17. PubMed ID: 7644431
[TBL] [Abstract][Full Text] [Related]
14. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
Wood MJA; Talbot K; Bowerman M
Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.
Cruz R; Belter L; Wasnock M; Nazarelli A; Jarecki J
Clin Ther; 2019 May; 41(5):943-960.e4. PubMed ID: 31056304
[TBL] [Abstract][Full Text] [Related]
16. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1.
Costamagna G; Govoni A; Wise A; Corti S
Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109
[TBL] [Abstract][Full Text] [Related]
17. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Chen TH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
[TBL] [Abstract][Full Text] [Related]
18. Moving towards treatments for spinal muscular atrophy: hopes and limits.
Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
[TBL] [Abstract][Full Text] [Related]
19. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.
Zhou H; Meng J; Malerba A; Catapano F; Sintusek P; Jarmin S; Feng L; Lu-Nguyen N; Sun L; Mariot V; Dumonceaux J; Morgan JE; Gissen P; Dickson G; Muntoni F
J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):768-782. PubMed ID: 32031328
[TBL] [Abstract][Full Text] [Related]
20. Prenatal diagnosis of spinal muscular atrophy in Russia.
Shagina I; Dadali HL; Sitnikov VP; Pugachev VV; Malygina NA; Evgrafov OV
Prenat Diagn; 1995 Jan; 15(1):27-34. PubMed ID: 7739994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
